Key facts
- Atalan’s last known valuation is $13.9M (May 2025).
- It has raised $7.0M; the latest was Seed Round ($4.2M) in May 2025.
- Notable investors include Ben Franklin Technology Partners of Southeastern Pennsylvania, Early Light Ventures, BioAdvance Capital (Conshohocken), Highpoint Ventures, Excelerate Health Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Atalan
- ·The full record, as it builds
Funding rounds
No funding rounds for Atalan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atalan
Developer of an early warning and monitoring platform designed to predict and prevent clinician burnout and turnover in the healthcare system. The company's platform uses machine learning to predict burnout and turnover, monthly trend analysis, financial impact projections, specialty-specific benchmarks, and evidence-based recommendations, enabling clinicians to identify and prioritize initiatives to increase provider efficiencies and financials.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 23
- Website
- atalantech.com/
- Ownership
- Privately Held (backing)
Atalan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atalan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atalan in its N-PORT filings yet. We sweep new filings monthly.